An abnormal kinase signaling network underlies the development and progression of tumors, and thus the targeted inhibition of protein kinases has become an attractive strategy in cancer treatment (for a recent review see Gross et al.6) and in the last decade the intense development in the field has led to different kinase inhibitors that have been approved for use in clinical therapy. Here, WEE1 is linked to cancer.